370 related articles for article (PubMed ID: 32097248)
1. Therapeutic Drug Monitoring Coupled With Bayesian Forecasting Could Prevent Vancomycin-Associated Nephrotoxicity in Renal Insufficiency Patients: A Prospective Study and Pharmacoeconomic Analysis.
Zhang Y; Wang T; Zhang D; You H; Dong Y; Liu Y; Du Q; Sun D; Zhang T; Dong Y
Ther Drug Monit; 2020 Aug; 42(4):600-609. PubMed ID: 32097248
[TBL] [Abstract][Full Text] [Related]
2. Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15-20 μg/mL concentration.
Oda K; Jono H; Nosaka K; Saito H
Int J Antimicrob Agents; 2020 Oct; 56(4):106109. PubMed ID: 32721597
[TBL] [Abstract][Full Text] [Related]
3. Clinical application of vancomycin TDM in ventilated patients with gastrointestinal cancer: a propensity-matched analysis.
Zhang X; Wu Y; Wang D
BMC Infect Dis; 2024 Jan; 24(1):10. PubMed ID: 38166695
[TBL] [Abstract][Full Text] [Related]
4. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients.
Pea F; Bertolissi M; Di Silvestre A; Poz D; Giordano F; Furlanut M
Int J Antimicrob Agents; 2002 Nov; 20(5):326-32. PubMed ID: 12431867
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
Fernández de Gatta MD; Calvo MV; Hernández JM; Caballero D; San Miguel JF; Domínguez-Gil A
Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin AUC-guided therapeutic drug monitoring to reduce nephrotoxicity: are we overlooking a simpler solution? Comment on: Oda K, Jono H, Nosaka K, Saito H. Reduced nephrotoxicity in vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against trough 15-20 µg/mL concentration.
Jorgensen SCJ; Stewart JJ; Dalton B
Int J Antimicrob Agents; 2020 Nov; 56(5):106150. PubMed ID: 32882431
[No Abstract] [Full Text] [Related]
7. Systematic review and meta-analysis to explore optimal therapeutic range of vancomycin trough level for infected paediatric patients with Gram-positive pathogens to reduce mortality and nephrotoxicity risk.
Kato H; Hagihara M; Okudaira M; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 Aug; 58(2):106393. PubMed ID: 34174409
[TBL] [Abstract][Full Text] [Related]
8. Impact of vancomycin therapeutic drug monitoring on patient care.
Welty TE; Copa AK
Ann Pharmacother; 1994 Dec; 28(12):1335-9. PubMed ID: 7696720
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort.
Al-Maqbali JS; Shukri ZA; Sabahi NA; Al-Riyami I; Al Alawi AM
J Infect Public Health; 2022 May; 15(5):589-593. PubMed ID: 35500543
[TBL] [Abstract][Full Text] [Related]
10. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring.
Slaughter RL; Cappelletty DM
Pharmacoeconomics; 1998 Oct; 14(4):385-94. PubMed ID: 10344906
[TBL] [Abstract][Full Text] [Related]
11. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis.
Ye ZK; Tang HL; Zhai SD
PLoS One; 2013; 8(10):e77169. PubMed ID: 24204764
[TBL] [Abstract][Full Text] [Related]
12. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
[TBL] [Abstract][Full Text] [Related]
13. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.
Kullar R; Leonard SN; Davis SL; Delgado G; Pogue JM; Wahby KA; Falcione B; Rybak MJ
Pharmacotherapy; 2011 May; 31(5):441-8. PubMed ID: 21923425
[TBL] [Abstract][Full Text] [Related]
14. [Level of evidence for therapeutic drug monitoring of vancomycin].
Jelassi ML; Benlmouden A; Lefeuvre S; Mainardi JL; Billaud EM;
Therapie; 2011; 66(1):29-37. PubMed ID: 21466775
[TBL] [Abstract][Full Text] [Related]
15. Determinants of vancomycin nephrotoxicity when administered to outpatients as a continuous 24-hour infusion.
Chambers ST; Long M; Gardiner SJ; Chin PKL; Yi M; Dalton SC; Drennan PG; Metcalf SCL
Int J Antimicrob Agents; 2020 Jun; 55(6):105972. PubMed ID: 32298746
[TBL] [Abstract][Full Text] [Related]
16. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
[TBL] [Abstract][Full Text] [Related]
17. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
18. Should the trough concentration of vancomycin be abandoned in therapeutic drug monitoring? A multicentre, retrospective study of critically ill patients without any form of dialysis.
Yu Z; Liu J; Yu H; Zhou L; Zhao Y; Zhong L; Zhu J; Liang G; Yang Y; Zheng Y; Yu L; Han G
Int J Antimicrob Agents; 2023 Jun; 61(6):106812. PubMed ID: 37037321
[TBL] [Abstract][Full Text] [Related]
19. A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug Monitoring.
Liang X; Fan Y; Yang M; Zhang J; Wu J; Yu J; Tao J; Lu G; Zhang H; Wang R; Wen X; Li H; Zhang F; Hang J; Shen L; Zhang Z; Lin Q; Fu F; Wu S; Shen B; Huang W; Chang C; Zhang H; Huang Q; Shi Y; Ren H; Yuan Q; Song X; Luo X; Zhang H
Clin Infect Dis; 2018 Nov; 67(suppl_2):S249-S255. PubMed ID: 30423040
[TBL] [Abstract][Full Text] [Related]
20. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.
Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS
Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
